Suppr超能文献

急性肾损伤是肝硬化患者的常见并发症,与不良预后相关。

Acute kidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury.

机构信息

Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis IN, USA.

Department of Computer Science, Purdue University, West Lafayette, IN USA.

出版信息

J Hepatol. 2022 Jul;77(1):108-115. doi: 10.1016/j.jhep.2022.02.009. Epub 2022 Feb 23.

Abstract

BACKGROUND & AIMS: Acute kidney disease (AKD) is the persistence of acute kidney injury (AKI) for up to 3 months, which is proposed to be the time-window where critical interventions can be initiated to alter downstream outcomes of AKI. In cirrhosis, AKD and its impact on outcomes have been scantly investigated. We aimed to define the incidence and outcomes associated with AKD in a nationwide US cohort of hospitalized patients with cirrhosis and AKI.

METHODS

Hospitalized patients with cirrhosis and AKI in the Cerner-Health-Facts database from 1/2009-09/2017 (n = 6,250) were assessed for AKD and were followed-up for 180 days. AKI and AKD were defined based on KDIGO and ADQI AKD and renal recovery consensus criteria, respectively. The primary outcome measure was mortality, and the secondary outcome measure was de novo chronic kidney disease (CKD). Competing-risk multivariable models were used to determine the independent association of AKD with primary and secondary outcomes.

RESULTS

AKD developed in 32% of our cohort. On multivariable competing-risk analysis adjusting for significant confounders, patients with AKD had higher risk of mortality at 90 (subdistribution hazard ratio [sHR] 1.37; 95% CI 1.14-1.66; p = 0.001) and 180 (sHR 1.37; 95% CI 1.14-1.64; p = 0.001) days. The incidence of de novo CKD was 37.5%: patients with AKD had higher rates of de novo CKD (64.0%) compared to patients without AKD (30.7%; p <0.001). After adjusting for confounders, AKD was independently associated with de novo CKD (sHR 2.52; 95% CI 2.01-3.15; p <0.001) on multivariable competing-risk analysis.

CONCLUSIONS

AKD develops in 1 in 3 hospitalized patients with cirrhosis and AKI and it is associated with worse survival and de novo CKD. Interventions that target AKD may improve outcomes of patients with cirrhosis and AKI.

LAY SUMMARY

In a nationwide US cohort of hospitalized patients with cirrhosis and acute kidney injury, acute kidney disease developed in 1 in 3 patients and was associated with worse survival and chronic kidney disease. Interventions that target acute kidney disease may improve outcomes of patients with cirrhosis and acute kidney injury.

摘要

背景与目的

急性肾损伤(AKI)持续时间达 3 个月即为急性肾疾病(AKD),这一时间窗被认为是可以启动关键干预措施来改变 AKI 下游结局的时间窗口。在肝硬化中,AKD 及其对结局的影响研究甚少。我们旨在定义美国全国范围内住院肝硬化合并 AKI 患者 AKD 的发生率及相关结局。

方法

从 2009 年 1 月至 2017 年 9 月 Cerner-Health-Facts 数据库中纳入肝硬化合并 AKI 的住院患者(n=6250),评估 AKD 并随访 180 天。AKI 和 AKD 分别根据 KDIGO 和 ADQI AKD 及肾脏恢复共识标准定义。主要结局指标为死亡率,次要结局指标为新发慢性肾脏病(CKD)。使用竞争风险多变量模型确定 AKD 与主要和次要结局的独立关联。

结果

本队列中 32%的患者发生 AKD。多变量竞争风险分析调整了显著混杂因素后,AKD 患者 90 天(亚分布危险比[ sHR]1.37;95%CI 1.14-1.66;p=0.001)和 180 天(sHR 1.37;95%CI 1.14-1.64;p=0.001)的死亡率风险更高。新发 CKD 的发生率为 37.5%:AKD 患者新发 CKD 发生率(64.0%)高于无 AKD 患者(30.7%;p<0.001)。调整混杂因素后,AKD 与新发 CKD 独立相关(多变量竞争风险分析 sHR 2.52;95%CI 2.01-3.15;p<0.001)。

结论

美国全国范围内住院肝硬化合并 AKI 患者中,1/3 患者发生 AKD,AKD 与生存不良和新发 CKD 相关。针对 AKD 的干预措施可能改善肝硬化合并 AKI 患者的结局。

置于此处

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验